De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Select Medical Holdings Beheer
Beheer criteriumcontroles 1/4
De CEO Select Medical Holdings' is David Chernow, benoemd in Jan2014, heeft een ambtstermijn van 10.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.71M, bestaande uit 9.3% salaris en 90.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.78% van de aandelen van het bedrijf, ter waarde $ 35.23M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.6 jaar en 10.2 jaar.
Belangrijke informatie
David Chernow
Algemeen directeur
US$10.7m
Totale compensatie
| Percentage CEO-salaris | 9.3% |
| Dienstverband CEO | 10.8yrs |
| Eigendom CEO | 0.8% |
| Management gemiddelde ambtstermijn | 1.6yrs |
| Gemiddelde ambtstermijn bestuur | 10.2yrs |
Recente managementupdates
Recent updates
Select Medical Holdings' (NYSE:SEM) Dividend Will Be $0.125
Aug 05
Select Medical Holdings' (NYSE:SEM) Returns On Capital Are Heading Higher
Jul 19What Does Select Medical Holdings Corporation's (NYSE:SEM) Share Price Indicate?
Jul 01Does Select Medical Holdings (NYSE:SEM) Have A Healthy Balance Sheet?
Jun 13There's Reason For Concern Over Select Medical Holdings Corporation's (NYSE:SEM) Price
May 26Results: Select Medical Holdings Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates
May 05Here's Why Shareholders Should Examine Select Medical Holdings Corporation's (NYSE:SEM) CEO Compensation Package More Closely
Apr 19Returns At Select Medical Holdings (NYSE:SEM) Appear To Be Weighed Down
Apr 11Select Medical: Solid Growth Prospects And A Compelling Valuation
Mar 05Cautious Investors Not Rewarding Select Medical Holdings Corporation's (NYSE:SEM) Performance Completely
Feb 18We Think Select Medical Holdings (NYSE:SEM) Is Taking Some Risk With Its Debt
Jan 15Returns On Capital At Select Medical Holdings (NYSE:SEM) Have Hit The Brakes
Dec 31Select Medical Holdings (NYSE:SEM) Is Due To Pay A Dividend Of $0.125
Nov 06Select Medical: Market Expectations Appear Well Justified With Technical And Economic Factors
Oct 25What Does Select Medical Holdings Corporation's (NYSE:SEM) Share Price Indicate?
Oct 04Is Select Medical Holdings (NYSE:SEM) Using Too Much Debt?
Sep 16Select Medical: Capital Charge Now $6.1Bn At C.6% Trailing Returns, Reiterate Hold
Aug 11Select Medical Holdings (NYSE:SEM) Will Pay A Dividend Of $0.125
Aug 07Select Medical Holdings (NYSE:SEM) Has More To Do To Multiply In Value Going Forward
Jul 14At US$31.69, Is Select Medical Holdings Corporation (NYSE:SEM) Worth Looking At Closely?
Jun 29Here's Why Select Medical Holdings (NYSE:SEM) Has A Meaningful Debt Burden
May 27Select Medical: Revising To Hold As Business Economics Roll Lower
May 26Select Medical Holdings (NYSE:SEM) May Have Issues Allocating Its Capital
Apr 05Should You Investigate Select Medical Holdings Corporation (NYSE:SEM) At US$25.73?
Mar 17Select Medical GAAP EPS of $0.22 misses by $0.11, revenue of $1.58B in-line
Feb 23Here's Why Select Medical Holdings (NYSE:SEM) Has A Meaningful Debt Burden
Jan 31The Returns On Capital At Select Medical Holdings (NYSE:SEM) Don't Inspire Confidence
Dec 20Is Now An Opportune Moment To Examine Select Medical Holdings Corporation (NYSE:SEM)?
Dec 01Select Medical declares $0.125 dividend
Nov 03These 4 Measures Indicate That Select Medical Holdings (NYSE:SEM) Is Using Debt Extensively
Nov 01Returns At Select Medical Holdings (NYSE:SEM) Appear To Be Weighed Down
Sep 16Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$259m |
| Mar 31 2024 | n/a | n/a | US$260m |
| Dec 31 2023 | US$11m | US$995k | US$235m |
| Sep 30 2023 | n/a | n/a | US$217m |
| Jun 30 2023 | n/a | n/a | US$196m |
| Mar 31 2023 | n/a | n/a | US$174m |
| Dec 31 2022 | US$9m | US$995k | US$153m |
| Sep 30 2022 | n/a | n/a | US$175m |
| Jun 30 2022 | n/a | n/a | US$223m |
| Mar 31 2022 | n/a | n/a | US$329m |
| Dec 31 2021 | US$12m | US$995k | US$389m |
| Sep 30 2021 | n/a | n/a | US$415m |
| Jun 30 2021 | n/a | n/a | US$415m |
| Mar 31 2021 | n/a | n/a | US$306m |
| Dec 31 2020 | US$8m | US$995k | US$250m |
| Sep 30 2020 | n/a | n/a | US$206m |
| Jun 30 2020 | n/a | n/a | US$162m |
| Mar 31 2020 | n/a | n/a | US$155m |
| Dec 31 2019 | US$8m | US$995k | US$143m |
| Sep 30 2019 | n/a | n/a | US$136m |
| Jun 30 2019 | n/a | n/a | US$138m |
| Mar 31 2019 | n/a | n/a | US$140m |
| Dec 31 2018 | US$8m | US$995k | US$133m |
| Sep 30 2018 | n/a | n/a | US$207m |
| Jun 30 2018 | n/a | n/a | US$193m |
| Mar 31 2018 | n/a | n/a | US$189m |
| Dec 31 2017 | US$7m | US$984k | US$171m |
Compensatie versus markt: De totale vergoeding ($USD 10.71M ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).
Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar met meer dan 20% gestegen.
CEO
David Chernow (67 yo)
10.8yrs
Tenure
US$10,706,265
Compensatie
Mr. David S. Chernow serves as Director at Exokinetics, Inc. He has been the Chief Executive Officer at Select Medical Holdings Corporation and Select Medical Corporation since January 1, 2014. Mr. Chernow...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 19.7yrs | US$10.77m | 6.89% $ 304.9m | |
| Chief Executive Officer | 10.8yrs | US$10.71m | 0.78% $ 34.4m | |
| Co-Founder & Chairman Emeritus | 27.7yrs | US$7.08m | 6.04% $ 267.7m | |
| Executive VP & CFO | less than a year | US$1.53m | 0.15% $ 6.9m | |
| Senior Executive VP | 27.7yrs | US$4.44m | 0.36% $ 15.8m | |
| Senior Executive Vice President of Strategic Finance & Operations | less than a year | US$6.47m | 1.01% $ 44.8m | |
| Co-President | less than a year | geen gegevens | 0.53% $ 23.7m | |
| Co-President | less than a year | geen gegevens | 0.28% $ 12.3m | |
| Senior VP | 1.6yrs | geen gegevens | 0.031% $ 1.4m | |
| Executive VP & Chief Information Officer | 3.8yrs | geen gegevens | 0.26% $ 11.5m | |
| Senior Vice President of Compliance & Audit | no data | geen gegevens | 0.029% $ 1.3m | |
| Senior VP & Chief Communications | less than a year | geen gegevens | geen gegevens |
1.6yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SEM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 19.7yrs | US$10.77m | 6.89% $ 304.9m | |
| Co-Founder & Chairman Emeritus | less than a year | US$7.08m | 6.04% $ 267.7m | |
| Independent Lead Director | 19.7yrs | US$384.40k | 0.84% $ 37.3m | |
| Independent Director | 20.7yrs | US$383.40k | 0.069% $ 3.0m | |
| Independent Director | 5.3yrs | US$405.80k | 0.051% $ 2.2m | |
| Independent Director | 14.4yrs | US$407.83k | 0.22% $ 9.7m | |
| Independent Director | 5.9yrs | US$394.40k | 0.042% $ 1.8m | |
| Independent Director | 15.9yrs | US$414.83k | 0.11% $ 5.0m | |
| Independent Director | 3.5yrs | US$409.80k | 0.035% $ 1.6m | |
| Independent Director | 2.9yrs | US$407.83k | 0.033% $ 1.5m |
10.2yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SEM zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.2 jaar).